STEMLINE THERAPEUTICS INC
NEW YORK, NY · CIK 0001264587 · Biotech · Acquired
Tagraxofusp-erzs, a CD123-directed cytotoxin for treating blastic plasmacytoid dendritic cell neoplasm
stemline.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $2.6M
- 3 Form D · Jan 2012
- 177 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 11 granted · 29 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2009201020112012
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,250,000 | |
| Private capital raised | Form D · SEC | $600,000 | |
| Private capital raised | Form D · SEC | $740,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2529 | ImmuneBridge Inc. | — | $16M |
| 2530 | IpiNovyx Bio, Inc. | — | $7.0M |
| 2531 | Lang Artificial Intelligence, Inc. | — | $11M |
| 2532 | STEMLINE THERAPEUTICS INC | — | $2.6M |
| 2533 | Form Bio | — | $16M |
| 2534 | A2 THERAPEUTICS, INC. | — | — |
| 2535 | Deverra Therapeutics | — | $2.5M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Ronald BentsurDirector
- Ivan BergsteinDirector · Executive Officer
- Ivan Bergstein, M.D.Director · Executive Officer
Patents
- Methods of Treating an Autoimmune Disease with a Human Interleukin-3 (IL-3)-Diphtheria Toxin Conjugate (DT-IL3)granted
- Combination Therapy Method of Treating Myeloproliferative Neoplasms with a Diphtheria Toxin-Human Interleukin-3 Conjugate in Combination with Other Agentsgranted
- Cancer Stem Cell Targeted Cancer Vaccinesgranted
- IL3Ra Antibody Conjugates and Uses Thereofapplication
- Inhibitors of Mutant RET Kinases for use in Treating Cancerapplication
- Improved Lyophilized Formulationapplication
- IL3Ralpha Antibodies and Uses Thereofgranted
- Lyophilized Formulationgranted
- Cancer Stem Cell-Targeted Cancer Therapyapplication
- Methods for Treating and Monitoring the Status of Cancerapplication
- Monitoring Cancer Stem Cellsapplication
- Cancer Stem Cell Targeted Cancer Vaccinesgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.